Nektar Therapeutics (NKTR)
NASDAQ: NKTR · IEX Real-Time Price · USD
1.570
-0.100 (-5.99%)
May 3, 2024, 4:00 PM EDT - Market closed
Nektar Therapeutics Revenue
In the year 2023, Nektar Therapeutics had annual revenue of $90.12M, a decrease of -2.10%. Revenue in the quarter ending December 31, 2023 was $23.89M with 8.45% year-over-year growth.
Revenue (ttm)
$90.12M
Revenue Growth
-2.10%
P/S Ratio
3.20
Revenue / Employee
$657,825
Employees
137
Market Cap
288.28M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 90.12M | -1.93M | -2.10% |
Dec 31, 2022 | 92.06M | -9.85M | -9.67% |
Dec 31, 2021 | 101.91M | -51.01M | -33.36% |
Dec 31, 2020 | 152.92M | 38.30M | 33.41% |
Dec 31, 2019 | 114.62M | -1.08B | -90.40% |
Dec 31, 2018 | 1.19B | 885.61M | 287.81% |
Dec 31, 2017 | 307.71M | 142.28M | 86.00% |
Dec 31, 2016 | 165.44M | -65.35M | -28.32% |
Dec 31, 2015 | 230.78M | 30.08M | 14.99% |
Dec 31, 2014 | 200.71M | 51.79M | 34.77% |
Dec 31, 2013 | 148.92M | 67.73M | 83.42% |
Dec 31, 2012 | 81.19M | 9.71M | 13.59% |
Dec 31, 2011 | 71.48M | -87.56M | -55.06% |
Dec 31, 2010 | 159.04M | 87.11M | 121.10% |
Dec 31, 2009 | 71.93M | -18.25M | -20.24% |
Dec 31, 2008 | 90.19M | -182.84M | -66.97% |
Dec 31, 2007 | 273.03M | 55.31M | 25.40% |
Dec 31, 2006 | 217.72M | 91.44M | 72.41% |
Dec 31, 2005 | 126.28M | 12.01M | 10.51% |
Dec 31, 2004 | 114.27M | 8.01M | 7.54% |
Dec 31, 2003 | 106.26M | 11.41M | 12.03% |
Dec 31, 2002 | 94.85M | 17.38M | 22.43% |
Dec 31, 2001 | 77.47M | 25.84M | 50.05% |
Dec 31, 2000 | 51.63M | 10.27M | 24.83% |
Dec 31, 1999 | 41.36M | 19.56M | 89.76% |
Dec 31, 1998 | 21.80M | 5.55M | 34.13% |
Dec 31, 1997 | 16.25M | 9.36M | 135.83% |
Dec 31, 1996 | 6.89M | 3.45M | 100.00% |
Dec 31, 1995 | 3.45M | 1.79M | 108.66% |
Dec 31, 1994 | 1.65M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Akebia Therapeutics | 194.62M |
Spok Holdings | 140.75M |
ChromaDex | 83.57M |
Nanobiotix | 40.23M |
TriSalus Life Sciences | 18.51M |
XOMA Corporation | 4.76M |
NKTR News
- 3 days ago - Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets - PRNewsWire
- 11 days ago - Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases - GlobeNewsWire
- 6 weeks ago - Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference - PRNewsWire
- 2 months ago - Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata - PRNewsWire
- 2 months ago - Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results - PRNewsWire
- 2 months ago - Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX - PRNewsWire
- 2 months ago - Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference - PRNewsWire
- 2 months ago - Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets - PRNewsWire